Alnylam Pharmaceuticals
ALNY
#634
Rank
โ‚น3.749 T
Marketcap
โ‚น28,095
Share price
-4.32%
Change (1 day)
21.51%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2025 (TTM): โ‚น51.41 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are โ‚น3.71 Billion. , an increase over its 2024 earnings that were of -โ‚น22.35 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2025

Annual earnings

Year Earnings Change
2025 โ‚น54.62 B-344.47%
2024 -โ‚น22.35 Billion-24.59%
2023 -โ‚น29.64 Billion-67.84%
2022 -โ‚น92.14 Billion36.93%
2021 -โ‚น67.29 Billion-8.04%
2020 -โ‚น73.17 Billion-15.66%
2019 -โ‚น86.75 Billion12.23%
2018 -โ‚น77.3 Billion62.91%
2017 -โ‚น47.45 Billion17.78%
2016 -โ‚น40.29 Billion43.44%
2015 -โ‚น28.09 Billion60.69%
2014 -โ‚น17.48 Billion98.2%
2013 -โ‚น8.82 Billion
2011 -โ‚น5.21 Billion27.48%
2010 -โ‚น4.08 Billion-10.92%
2009 -โ‚น4.59 Billion95.77%
2008 -โ‚น2.34 Billion
2006 -โ‚น3.75 Billion-9.13%
2005 -โ‚น4.13 Billion34.74%
2004 -โ‚น3.07 Billion36.79%
2003 -โ‚น2.24 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Novartis
NVS
โ‚น1.551 T 2,739.98%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
โ‚น730.50 B 1,237.20%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
โ‚น496.28 B 808.46%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-โ‚น66.63 Billion-221.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-โ‚น4.51 Billion-108.24%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-โ‚น15.14 Billion-127.70%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
โ‚น204.18 B 273.75%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
โ‚น32.74 B-40.06%๐Ÿ‡บ๐Ÿ‡ธ USA